BB&T Securities LLC Sells 249 Shares of Davita Inc (NYSE:DVA)

BB&T Securities LLC decreased its holdings in Davita Inc (NYSE:DVA) by 3.7% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 6,500 shares of the company’s stock after selling 249 shares during the quarter. BB&T Securities LLC’s holdings in Davita were worth $383,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Flinton Capital Management LLC grew its stake in shares of Davita by 3.3% in the second quarter. Flinton Capital Management LLC now owns 187,884 shares of the company’s stock worth $10,571,000 after purchasing an additional 6,052 shares during the last quarter. Campbell & CO Investment Adviser LLC bought a new stake in shares of Davita in the second quarter worth $493,000. Northstar Group Inc. grew its stake in shares of Davita by 33.2% in the second quarter. Northstar Group Inc. now owns 9,082 shares of the company’s stock worth $511,000 after purchasing an additional 2,266 shares during the last quarter. Wedge Capital Management L L P NC grew its stake in shares of Davita by 28.8% in the second quarter. Wedge Capital Management L L P NC now owns 37,691 shares of the company’s stock worth $2,120,000 after purchasing an additional 8,434 shares during the last quarter. Finally, GVO Asset Management Ltd bought a new stake in shares of Davita in the second quarter worth $2,644,000. 91.27% of the stock is currently owned by institutional investors.

Shares of DVA opened at $69.30 on Thursday. The company has a current ratio of 1.81, a quick ratio of 1.77 and a debt-to-equity ratio of 4.26. The stock has a market capitalization of $9.07 billion, a P/E ratio of 19.41, a price-to-earnings-growth ratio of 0.57 and a beta of 1.59. The firm’s fifty day simple moving average is $59.29 and its two-hundred day simple moving average is $56.04. Davita Inc has a 12 month low of $43.40 and a 12 month high of $70.51.

Davita (NYSE:DVA) last issued its quarterly earnings results on Tuesday, November 5th. The company reported $1.53 EPS for the quarter, beating the Zacks’ consensus estimate of $1.24 by $0.29. The business had revenue of $2.90 billion for the quarter, compared to analysts’ expectations of $2.85 billion. Davita had a net margin of 3.68% and a return on equity of 19.95%. The business’s quarterly revenue was up 2.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.56 earnings per share. As a group, research analysts predict that Davita Inc will post 5.31 EPS for the current fiscal year.

DVA has been the topic of several analyst reports. William Blair cut shares of Davita from an “outperform” rating to a “market perform” rating in a research note on Wednesday, September 11th. UBS Group reduced their price objective on shares of Davita from $61.00 to $60.00 and set a “neutral” rating on the stock in a research note on Thursday, August 22nd. Wolfe Research cut shares of Davita from an “outperform” rating to a “market perform” rating and set a $57.00 price objective on the stock. in a research note on Friday, October 25th. ValuEngine cut shares of Davita from a “hold” rating to a “sell” rating in a research note on Thursday. Finally, Raymond James cut shares of Davita from an “outperform” rating to a “market perform” rating in a research note on Thursday, November 7th. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and two have given a buy rating to the stock. Davita presently has an average rating of “Hold” and an average price target of $64.81.

Davita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.

See Also: Retained Earnings

Want to see what other hedge funds are holding DVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Davita Inc (NYSE:DVA).

Institutional Ownership by Quarter for Davita (NYSE:DVA)

Receive News & Ratings for Davita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davita and related companies with MarketBeat.com's FREE daily email newsletter.